Psychometric assessment of the Concerns about Late Effects in Oncology Questionnaire (CLEO) among female breast cancer survivors

Patient Educ Couns. 2022 Nov;105(11):3298-3305. doi: 10.1016/j.pec.2022.08.008. Epub 2022 Aug 17.

Abstract

Objective: The Concerns about Late Effects in Oncology (CLEO) questionnaire was developed to measure concerns cancer survivors may have about late effects. The current study sought to assess the Concerns about Late Effects in Oncology's (CLEO) psychometric properties - factor structure, construct validity, discriminatory power, and internal consistency.

Methods: 147 breast cancer survivors completed a survey. Factor structure was determined by exploratory factor analysis (EFA). Construct validity was assessed against fear of cancer recurrence, anxiety, depression, quality of life, and neuroticism. Discriminatory power was assessed against participants' age and clinical characteristics.

Results: The EFA confirmed a 4-factor structure; health professionals' support, psychological impacts, adapting, and daily functional impacts. There was only partial support for construct validity and discriminatory power. The CLEO demonstrated excellent internal consistency, with an overall Cronbach's α = 0.87 (health professionals' support: α = 0.89, psychological impacts: α = 0.93, adapting: α = 0.82, and daily functional impacts: α = 0.89).

Conclusion: The findings suggest further development of the CLEO should focus on the psychological and functional impacts of late effects.

Practice implications: Use of the CLEO may enhance communication about the impact of late effects, ensuring earlier identification and management of late effects in this population.

Keywords: Breast cancer survivors; Concerns; Late effects; Psychometrics; Questionnaire development.

MeSH terms

  • Breast Neoplasms* / psychology
  • Cancer Survivors* / psychology
  • Female
  • Humans
  • Neoplasm Recurrence, Local
  • Psychometrics
  • Quality of Life
  • Reproducibility of Results
  • Surveys and Questionnaires